This study aimed to investigate the mutations in the serine protease 1 gene (PRSS1) and the imbalance between trypsin and α1-antitrypsin in patients with pancreatic cancer. Polymerase chain reaction (PCR) was performed to amplify the sequences of PRSS1 from 65 patients with pancreatic cancer and 260 healthy controls, direct sequencing was performed, and the clinical features were analyzed. In addition, enzyme-linked immunosorbent assay (ELISA) was employed to detect serum trypsin and α1-antitrypsin in pancreatic cancer patients and healthy controls in the same period. Mutations were found at the promoter and exon 3 of the PRSS1 in patients with pancreatic cancer. That is, five patients had c.410 C > T mutation causing p.Thr 137 Met, and three patients had c. −338 T > G mutation at the promoter of the PRSS1. In patients with PRSS1 mutations, serum trypsin was 34.5 ± 18.3 ng/mL, which was significantly higher than that in normal controls (10.65 ± 6.03 ng/mL) and other pancreatic cancer (28.61 ± 8.96 ng/mL). What is more, in pancreatic cancer patients, serum α1-antitrypsin was 1.69 ± 0.86 g/L, which was comparable to that in normal controls (1.55 ± 0.53 g/L), while the ratio of serum trypsin to α1-antitrypsin was 1.46-fold to normal controls. The results presented here have provided a greater insight into the PRSS1 mutations and proteinase-inhibitor interactions occurring in pancreatic cancer.
PRSS1 mutations α1-antitrypsin Pancreatic cancer Enzyme kinetics Serine proteinase
This is a preview of subscription content, log in to check access.
This work was supported by the National Natural Science Foundation of China (81572442, 81571613, 81201362, 81201590, and 21275028) and financially supported by the Natural Science Foundation of Fujian Province (2013 J01302), Outstanding Youth Foundation of Fujian Provincial Higher Education (JA12133), and National High Technology Investigation Project Foundation of China (2012AA022604).
Conflicts of interest
Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556–64.CrossRefPubMedGoogle Scholar
Gao J, Wang LH, Xu JK, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013;32:86–95.CrossRefPubMedPubMedCentralGoogle Scholar
Yamamoto H, Iku S, Adachi Y, et al. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol. 2003;199:176–84.CrossRefPubMedGoogle Scholar
Mohammed A, Janakiram NB, Pant S, et al. Molecular targeted intervention for pancreatic cancer. Cancers (Basel). 2015;7:1499–542.CrossRefGoogle Scholar
Zeng K, Liu QC, Lin JH, et al. Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population. Chin Med J (Engl). 2011;124:2065–7.Google Scholar
Applebaum-Shapiro SE, Peters JA, O’Connell JA, et al. Motivations and concerns of patients with access to genetic testing for hereditary pancreatitis. Am J Gastroenterol. 2001;96:1610–7.CrossRefPubMedGoogle Scholar
Lin K, Gao F, Chen QQ, et al. Framework for interpretation of trypsin-antitrypsin imbalance and genetic heterogeneity in pancreatitis. Saudi J Gastroenterol. 2015;21:198–207.CrossRefPubMedPubMedCentralGoogle Scholar
Koskensalo S, Hagstrom J, Louhimo J, et al. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer. Oncology. 2012;82:234–41.CrossRefPubMedGoogle Scholar
Parker LA, Porta M, Lumbreras B, et al. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol. 2011;26:229–36.CrossRefPubMedGoogle Scholar
Johansen D, Manjer J, Regner S, et al. Pre-diagnostic levels of anionic trypsinogen, cationic trypsinogen, and pancreatic secretory trypsin inhibitor in relation to pancreatic cancer risk. Pancreatology. 2010;10:229–37.CrossRefPubMedGoogle Scholar
Tawara I, Sun Y, Lewis EC, et al. Alpha-1-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109:564–9.CrossRefPubMedGoogle Scholar
Cenac N, Cellars L, Steinhoff M, et al. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis. 2005;11:792–8.CrossRefPubMedGoogle Scholar
Kereszturi E, Sahin-Toth M. Intracellular autoactivation of human cationic trypsinogen mutants causes reduced trypsinogen secretion and acinar cell death. J Biol Chem. 2009;284:33392–9.CrossRefPubMedPubMedCentralGoogle Scholar
Tang D, Gao J, Wang S, et al. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumour Biol. 2015;36:5617–26.CrossRefPubMedGoogle Scholar
Caruso R, Pallone F, Fina D, et al. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor trans-activation and proliferation. Am J Pathol. 2006;169:268–78.CrossRefPubMedPubMedCentralGoogle Scholar
Dangi-Garimella SB, Krantz MR, Barron MA, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011;71:1019–28.CrossRefPubMedGoogle Scholar